ArticleSurgical case reports2025
Neoadjuvant Chemotherapy for Stage II Rectal Cancer Diagnosed in the Second Trimester of Pregnancy: A Case Report.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe onset of colorectal cancer during pregnancy is rare, and no standard treatment has been established. In this report, we present the case of a woman with clinical stage II rectal cancer diagnosed in the second trimester, in which neoadjuvant chemotherapy was administered, followed by delivery once fetal development was sufficiently advanced, and surgery was performed afterward. CASE PRESENTATION: The patient was a 36-year-old woman at 22 weeks of gestation. Sigmoidoscopy was performed for hematochezia, which revealed a semicircular type 2 tumor in the rectum. A biopsy confirmed the presence of adenocarcinoma. A thorough systemic examination revealed no lymph nodes or distant metastases. After discussing the risks and benefits with the patient, her family, a pediatrician, and an obstetrician, we decided to administer neoadjuvant chemotherapy. The plan was to deliver the fetus after it had adequately developed and then perform radical surgery for rectal cancer after delivery. Neoadjuvant chemotherapy comprised 4 courses of the modified FOLFOX6 regimen, including leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin. The patient had a vaginal delivery at 35 weeks and 5 days of gestation, 23 days after the last chemotherapy dose. The newborn was healthy with no congenital anomalies. On the 27th day after delivery, a robot-assisted low anterior resection of the rectum was performed. The pathological findings revealed rectal cancer located above the peritoneal reflection, ypT2N0M0, and ypStage I. The patient recovered well and was discharged 12 days after surgery. At the time of writing, both the mother and child are doing well, with no evidence of recurrence 6 months after surgery.
conclusionsIn cases of colorectal cancer during pregnancy, it is important to select a treatment plan that considers the site and stage of the tumor, number of weeks of pregnancy, and conditions of the fetus and mother. Even in cases of clinical stage II colorectal cancer diagnosed during the second trimester, where immediate surgery is not feasible, neoadjuvant chemotherapy can be considered a viable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.